Search
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawn[DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965].
Befunolol
go.drugbank.com/drugs/DB09013ExperimentalBefunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Armodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigationalFood and Drug Administration (FDA) in June 2007. … Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil.
Products: ARVIGIL FT COMPRIMIDOS 200MG, นูวิจิล (150 MG)Temocapril
go.drugbank.com/drugs/DB08836InvestigationalTemocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. … Temocapril can also be used in hemodialysis patients without risk of serious accumulation.
Categories: Agents Acting on the Renin-Angiotensin SystemSalix alba bark volatile oil
go.drugbank.com/drugs/DB14354InvestigationalSalix alba bark volatile oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
BCc1
go.drugbank.com/drugs/DB16504ExperimentalBCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.
Rosemary
go.drugbank.com/drugs/DB14272InvestigationalRosemary is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Indocyanine green
go.drugbank.com/drugs/DB16024ApprovedInvestigationalWithdrawnCategories: Compounds used in a research, industrial, or household settingOT-730
go.drugbank.com/drugs/DB16112InvestigationalOT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma).
Drinabant
go.drugbank.com/drugs/DB05750InvestigationalIt is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.